Andrew Dalovisio

Statistics

Publications

Citations

389

H-Index

Active since

2017

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

University of Calgary

Massachusetts General Hospital

McGill University Health Centre

Institute of Cancer Research

Andrew Dalovisio is an author at Memorial Sloan Kettering Cancer Center specializing in multiple myeloma treatment, multiple myeloma, and refractory multiple myeloma.

Publications per year

2017–2023

Publications

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Nizar J. Bahlis, Caitlin Costello, Noopur Raje et al. · Nature Medicine · 2023 · 142 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Michaël Sébag, Noopur Raje, Nizar J. Bahlis et al. · Blood · 2021 · 55 citations

Life Sciences, Immunology, Pharmacology +16

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar J. Bahlis, Caitlin Costello et al. · Blood · 2022 · 46 citations

Medicine, Immunology, Oncology +16

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

Nizar J. Bahlis, Noopur Raje, Caitlin Costello et al. · Journal of Clinical Oncology · 2021 · 42 citations

Medicine, Hematology, Pharmacology +17

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

Laura Finn, Andrew Dalovisio, James M. Foran · PubMed · 2017 · 36 citations · Full text

Medicine, Hematology, Oncology +17

1–5 of 8